Umbilical Cord Mesenchymal Stem Cell Therapy and Secretome as Immunotherapy in Polycystic Ovary Syndrome (PCOS) Patients with Insulin Resistance

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
Gatot Soebroto Army Hospital
No Registry
INA-6XRFEC60
Tanggal Input Registry : 31-01-2025

15-09-2022
Improving insulin resistance in PCOS patients, leading to improvements in menstrual cycles and fertility
 
Umbilical Cord Mesenchymal Stem Cell Therapy and Secretome as Immunotherapy in Polycystic Ovary Syndrome (PCOS) Patients with Insulin Resistance
Umbilical Cord Mesenchymal Stem Cell Therapy and Secretome as Immunotherapy in Polycystic Ovary Syndrome (PCOS) Patients with Insulin Resistance
Interventional
Umbilical Cor Mesenshymal Stem Cell (UCMSC) and Conditioned Medium Umbilical Cor Mesenshymal Stem Cell (CM-UCMSC)
40
 

Inclusion Criteria:

PCOS patients with insulin resistance are diagnosed based on the Rotterdam Consensus criteria, which include menstrual disturbances (oligomenorrhea/amenorrhea),clinical and laboratory evidence of hyperandrogenemia, Free Androgen Index (FAI) > 4, and polycystic ovaries observed through transvaginal ultrasound, HOMA IR score > 1.

Exclusion Criteria:

Patient is allergic to one of the components of UC-MSC or its secretome, not undergoing hormone treatment or other insulin resistance treatments, refuses or does not comply with some/all of the study process, diagnosed positive for hepatitis A, B, C, and HIV.
 
54/KEPK/III/2024
Not applicable
Not applicable
Rima Haifa,S,Si.,M.Farm-Klin